For companies conducting clinical trials, study startup remains a major hurdle. A new report from Industry Standard Research (ISR) titled, eClinical Technology Adoption and Challenges in Study Startup, shines a light on the issues surrounding startup and how eClinical technologies are helping companies overcome these challenges.
Our rapidly increasing genetic-level disease knowledge and exponential technology advances are changing the way we manage health. But we may never fully seize these opportunities if we limit our clinical research approach to past models. Changing societal attitudes around sharing personal data and new consumer technology make innovative study designs and operations possible. This includes new possibilities in designing and operationalizing patient registries by moving to “virtual” setups.
Everyone would like to have a quicker study start-up process. In many companies the process and the paperwork have not changed for decades, and the process is always time-consuming. Here is one company’s journey to a study start-up solution.
The ubiquitous nature of mobile devices means mining and monitoring social media channels and managing the challenges associated with them through technology, process management, and tactical outsourcing need to be considered standard operating procedure for clinical trials professionals and organizations.
I recently reported on data collected from Fitbit activity trackers. Fitbit has compiled 150 billion hours of data on the resting heart rate (RHR) of tens of millions of people around the world who used a Fitbit. Can this type of data help researchers, especially cardiologists, conduct better clinical trials on heart patients in the future?
David Pogue, a tech columnist for Yahoo Finance, notes Fitbit has collected 150 billion hours of heart-rate data from tens of millions of people all over the world. In January, Fitbit gave Pogue a deep dive into the data it collected. The finding may bode well for the use of activity trackers in future trials.
A new brief by CB Insights focuses on AI and its potential to transform clinical trials. A makeover of the $65 billion clinical trials market is well overdue. With all of the issues that seem to be preventing more efficient trials, will AI be the technology that finally streamlines the process?
Adverse events (a suspected reaction to the API or to the API in combination with prescribed medicines or environmental factors) are, naturally, a challenging situation for patients in a clinical trial and may, in rare cases, become severe or even fatal. For sponsors, contract research organizations (CROs), and logistics partners, early notification and accurate information is vital to understanding and responding to a suspected adverse event. What happens if the patient goes off protocol and turns to social media?
The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials. This is the second of two articles that shares interview findings and insights published in the new Deloitte report, Digital R&D: Transforming the future of clinical development.
Sudip Parikh, SVP & managing director, Americas at DIA Global, sees two trends that will continue to have a profound impact on potentially powerful new treatments and the clinical trials that make them possible. Both will be front and center at DIA’s 2018 Annual Meeting.
|
|
|
|
|
|
|
|
|